INXN 2001

Drug Profile

INXN 2001

Alternative Names: Ad-IL-12; Ad-RTS-hIL-12; Ad-RTS-IL-12; Ad-RTS-mIL-12; Adenoviral-vector-interleukin-12-gene-therapy-ZIOPHARM-Oncology; INXN2001; ZIN-ATI-001

Latest Information Update: 27 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ZIOPHARM Oncology
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Gene transference; Interleukin-12 expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I Glioblastoma; Glioma
  • Suspended Malignant melanoma
  • Discontinued Colorectal cancer

Most Recent Events

  • 01 Sep 2018 ZIOPHARM initiates a phase I trial for Glioblastoma (Combination therapy, In adults, Recurrent) in USA (NCT03679754)
  • 28 Jun 2018 No recent reports of development identified for phase-I development in Glioma(Combination therapy, Recurrent, Second-line therapy or greater) in USA (Intratumoural, Injection)
  • 04 Jun 2018 Pharmacodynamics data from phase Ib/II and phase I trials in Breast cancer and Glioblastoma, respectively, presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top